Enveric Biosciences, Inc. ENVB
the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior
to the completion of a "reverse merger" transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation
and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. ("Ameri and Partners"), a Delaware
corporation (the "2015 Merger"). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc.
Last close
1.40
2026-10-23
Market cap
$6.3M
2026-06-30 share count
52-week range
1.17 - 13.25
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-36.24
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $39.9M | $43.0M | $48.6M | $36.1M |
| Cost of revenue | — | — | — | — | — | — | $31.8M | $34.0M | $38.4M | $29.2M |
| Gross profit | — | — | — | — | — | — | $8.2M | $9.0M | $10.2M | $6.9M |
| R&D | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174.1K | — | — | — | $55.1K |
| SG&A | $5.8M | $6.5M | $8.9M | $11.6M | $20.5M | $5.3M | $2.3M | $10.8M | $18.5M | $9.4M |
| Total operating expenses | — | — | — | — | — | — | $14.5M | $16.1M | $21.1M | $12.3M |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M | -$5.6M | -$2.3M | -$7.1M | -$10.9M | -$5.4M |
| Interest expense | $106 | $219 | $3.7K | $5.2K | $10.3K | $445.2K | $81.8K | $729.9K | $575.0K | $751.1K |
| Pre-tax income | -$8.8M | -$9.6M | -$17.3M | -$20.0M | -$56.4M | -$6.9M | -$5.2M | -$10.5M | -$11.5M | -$6.5M |
| Income tax | — | $8.9K | $28.9K | $1.5M | $7.5M | — | $388.7K | $6.3M | $2.4M | $3.7M |
| Net income | $12.1M | $9.6M | $17.5M | -$18.5M | -$49.0M | -$6.9M | -$2.4M | -$16.9M | -$9.1M | -$2.8M |
| EPS, basic | -36.24 | -228.48 | -121.29 | -13.00 | -103.69 | — | -2.83 | -20.47 | -0.75 | -0.21 |
| EPS, diluted | -36.24 | -228.48 | -121.29 | -13.00 | -2.07 | -1.19 | -0.46 | -20.47 | -0.75 | -0.21 |
| Shares, diluted (wtd. avg.) | 334,719 | 41,908 | 143,938 | 1.4M | 472,343 | 5.8M | 5.3M | 951,601 | 15.0M | 13.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | — | $1.6M | $43.7K | $113.7K | $4.9M | $1.4M |
| Receivables | — | — | — | — | — | — | $6.4M | $7.9M | $8.8M | $8.1M |
| Total current assets | $4.9M | $2.7M | $3.6M | $18.4M | $17.7M | $2.3M | $108.8K | $10.1M | $14.6M | $10.1M |
| Property, plant and equipment | $159.2K | $305.8K | $507.4K | $677.5K | $294.4K | — | $83.1K | $58.9K | $95.0K | $100.2K |
| Goodwill | — | — | — | — | $1.6M | — | $13.7M | $13.7M | $21.9M | $17.1M |
| Other intangibles | — | $42.2K | $210.9K | $379.7K | $548.4K | $1.8M | $0 | $5.8M | $9.5M | $8.8M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M | $4.1M | $108.8K | $29.6M | $52.2M | $39.5M |
| Accounts payable | $581.0K | $521.7K | $1.2M | $463.3K | $683.4K | — | $4.7M | $4.4M | $5.3M | $5.1M |
| Short-term debt | — | — | — | — | — | — | $4.9M | $5.2M | $749.6K | $405.4K |
| Total current liabilities | $918.4K | $1.5M | $2.3M | $4.0M | $2.7M | $681.2K | $13.5M | $14.7M | $30.4M | $12.7M |
| Long-term debt | — | — | — | — | — | — | $740.3K | $0 | $1.1M | $1.5M |
| Total liabilities | — | — | — | $4.0M | $4.4M | $681.2K | $1.9M | $18.9M | $32.7M | $27.8M |
| Retained earnings | -$114.8M | -$106.1M | -$96.5M | -$79.2M | -$60.7M | -$11.8M | -$4.9M | -$34.5M | -$15.0M | -$3.8M |
| Total equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M | $3.4M | -$1.8M | -$65.5K | $19.4M | $11.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M | -$3.9M | -$647.9K | -$2.6M | -$2.7M | -$2.7M |
| Depreciation and amortisation | $158.7K | $168.7K | $175.2K | $159.2K | $13.3K | — | — | — | — | $1.4M |
| Stock-based compensation | $827.3K | $1.6M | $2.2M | $2.6M | $12.6M | $2.0M | $624.1K | — | $7.1M | $1.5M |
| Capital expenditure | — | — | $5.2K | $584.2K | $189.7K | — | — | — | — | — |
| Investing cash flow | — | — | $11.7K | -$584.2K | $2.2M | -$44.1K | -$284.3K | -$3.6M | -$169.9K | -$6.6M |
| Financing cash flow | $10.6M | $7.7M | -$1.3M | $18.2M | $24.9M | $5.5M | $560.0K | $2.7M | $6.4M | $8.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016543.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $48.6M | $43.0M | $39.9M | — | — | — | — | — | — |
| Gross profit | $6.9M | $10.2M | $9.0M | $8.2M | — | — | — | — | — | — |
| Net income | -$2.8M | -$9.1M | -$16.9M | -$2.4M | -$6.9M | -$49.0M | -$18.5M | $17.5M | $9.6M | $12.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |